Pharvaris (NASDAQ:PHVS) Trading Down 3.2% – Should You Sell?

Shares of Pharvaris (NASDAQ:PHVS) traded down 3.2% during trading on Wednesday . The stock traded as low as $15.94 and last traded at $15.97. 29,290 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 70,377 shares. The stock had previously closed at $16.50.

Analyst Upgrades and Downgrades

Separately, JMP Securities raised their price target on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Stock Down 3.9 %

The business has a 50-day simple moving average of $16.92 and a 200-day simple moving average of $19.06. The stock has a market cap of $808.40 million, a P/E ratio of -5.52 and a beta of -3.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of Pharvaris in the third quarter valued at about $526,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pharvaris in the 3rd quarter valued at approximately $906,000. State Street Corp bought a new position in Pharvaris in the 3rd quarter worth approximately $1,000,000. Geode Capital Management LLC lifted its holdings in shares of Pharvaris by 18.4% during the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after buying an additional 5,753 shares during the last quarter. Finally, Barclays PLC bought a new stake in shares of Pharvaris in the third quarter valued at approximately $106,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.